{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:52:27Z","timestamp":1790409147324,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA 008748"],"award-info":[{"award-number":["P30 CA 008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Carfilzomib-lenalidomide-dexamethasone (KRd) therapy has yielded promising results in patients with newly diagnosed multiple myeloma (NDMM). Cereblon (CRBN) is the direct molecular target of lenalidomide and genetic polymorphisms in <jats:italic>CRBN<\/jats:italic> have been associated with lenalidomide efficacy. In this study, we assessed the correlation of five single nucleotide variants (SNVs) in the <jats:italic>CRBN<\/jats:italic> gene with clinical response and outcomes in patients with NDMM administered KRd therapy with lenalidomide maintenance, achieving favorable trial endpoints in a prospective Phase II study (NCT01402284). Of the observed SNVs, no associations with KRd therapy response were found in this patient cohort, although strong trends in hypoalbuminemia grade and hyperbilirubinemia grade emerged across the <jats:italic>CRBN<\/jats:italic> rs1672753 genotype (P\u2009=\u20090.0008) and the rs1714327 genotype (P\u2009=\u20090.0010), respectively. Our results do not provide conclusive support for the predictive utility of <jats:italic>CRBN<\/jats:italic> gene polymorphisms as potential biomarkers of clinical response to lenalidomide-based therapy in our patient population. However, these findings remain to be validated in prospective studies using larger patient populations.<\/jats:p>","DOI":"10.1038\/s41598-019-51446-9","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T10:07:34Z","timestamp":1571220454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide"],"prefix":"10.1038","volume":"9","author":[{"given":"Phoebe A.","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaunna L.","family":"Beedie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy H.","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8990-158X","authenticated-orcid":false,"given":"David J.","family":"Venzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Gere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickran","family":"Kazandjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-4318","authenticated-orcid":false,"given":"Neha","family":"Korde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"51446_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15761\/HMO.1000129","volume":"2","author":"O Fuchs","year":"2017","unstructured":"Fuchs, O. Immunomodulatory drugs and their therapeutic effect in hematological malignancies through cereblon. Hematology & Medical Oncology 2, 1\u20138, https:\/\/doi.org\/10.15761\/HMO.1000129 (2017).","journal-title":"Hematology & Medical Oncology"},{"key":"51446_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","volume":"77","author":"SA Holstein","year":"2017","unstructured":"Holstein, S. A. & McCarthy, P. L. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. Drugs 77, 505\u2013520, https:\/\/doi.org\/10.1007\/s40265-017-0689-1 (2017).","journal-title":"Drugs"},{"key":"51446_CR3","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","volume":"118","author":"YX Zhu","year":"2011","unstructured":"Zhu, Y. X. et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118, 4771\u20134779, https:\/\/doi.org\/10.1182\/blood-2011-05-356063 (2011).","journal-title":"Blood"},{"key":"51446_CR4","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","volume":"120","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak, A. J. et al. A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 120, 1801\u20131809, https:\/\/doi.org\/10.1182\/blood-2012-04-422683 (2012).","journal-title":"Blood"},{"key":"51446_CR5","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","volume":"1","author":"N Korde","year":"2015","unstructured":"Korde, N. et al. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA. Oncol 1, 746\u2013754, https:\/\/doi.org\/10.1001\/jamaoncol.2015.2010 (2015).","journal-title":"Oncol"},{"key":"51446_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart, A. K. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372, 142\u2013152, https:\/\/doi.org\/10.1056\/NEJMoa1411321 (2015).","journal-title":"N Engl J Med"},{"key":"51446_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","volume":"24","author":"H Quach","year":"2010","unstructured":"Quach, H. et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24, 22\u201332, https:\/\/doi.org\/10.1038\/leu.2009.236 (2010).","journal-title":"Leukemia"},{"key":"51446_CR8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345\u20131350, https:\/\/doi.org\/10.1126\/science.1177319 (2010).","journal-title":"Science"},{"key":"51446_CR9","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona, A. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26, 2326\u20132335, https:\/\/doi.org\/10.1038\/leu.2012.119 (2012).","journal-title":"Leukemia"},{"key":"51446_CR10","first-page":"287","volume":"2","author":"XB Chang","year":"2011","unstructured":"Chang, X. B. & Stewart, A. K. What is the functional role of the thalidomide binding protein cereblon? Int J Biochem Mol Biol 2, 287\u2013294 (2011).","journal-title":"Int J Biochem Mol Biol"},{"key":"51446_CR11","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","volume":"132","author":"EC Fink","year":"2018","unstructured":"Fink, E. C. et al. Crbn (I391V) is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood 132, 1535\u20131544, https:\/\/doi.org\/10.1182\/blood-2018-05-852798 (2018).","journal-title":"Blood"},{"key":"51446_CR12","doi-asserted-by":"publisher","first-page":"11802","DOI":"10.1073\/pnas.1814446115","volume":"115","author":"Y Gemechu","year":"2018","unstructured":"Gemechu, Y. et al. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs. Proc Natl Acad Sci USA 115, 11802\u201311807, https:\/\/doi.org\/10.1073\/pnas.1814446115 (2018).","journal-title":"Proc Natl Acad Sci USA"},{"key":"51446_CR13","doi-asserted-by":"publisher","first-page":"6187","DOI":"10.1074\/jbc.M117.816868","volume":"293","author":"AA Akuffo","year":"2018","unstructured":"Akuffo, A. A. et al. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. J Biol Chem 293, 6187\u20136200, https:\/\/doi.org\/10.1074\/jbc.M117.816868 (2018).","journal-title":"J Biol Chem"},{"key":"51446_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/srep21419","volume":"6","author":"Y Kazuki","year":"2016","unstructured":"Kazuki, Y. et al. Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model. Sci Rep 6, 21419, https:\/\/doi.org\/10.1038\/srep21419 (2016).","journal-title":"Sci Rep"},{"key":"51446_CR15","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood-2012-06-438101","volume":"121","author":"A Broyl","year":"2013","unstructured":"Broyl, A. et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 121, 624\u2013627, https:\/\/doi.org\/10.1182\/blood-2012-06-438101 (2013).","journal-title":"Blood"},{"key":"51446_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ejh.12457","volume":"95","author":"A Jonasova","year":"2015","unstructured":"Jonasova, A. et al. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide. Eur J Haematol 95, 27\u201334, https:\/\/doi.org\/10.1111\/ejh.12457 (2015).","journal-title":"Eur J Haematol"},{"key":"51446_CR17","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.3892\/ol.2017.6502","volume":"14","author":"Y Jian","year":"2017","unstructured":"Jian, Y. et al. Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels. Oncol Lett 14, 3243\u20133248, https:\/\/doi.org\/10.3892\/ol.2017.6502 (2017).","journal-title":"Oncol Lett"},{"key":"51446_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/bjh.12338","volume":"161","author":"D Heintel","year":"2013","unstructured":"Heintel, D. et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol 161, 695\u2013700, https:\/\/doi.org\/10.1111\/bjh.12338 (2013).","journal-title":"Br J Haematol"},{"key":"51446_CR19","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.3324\/haematol.2017.186601","volume":"103","author":"LE Franssen","year":"2018","unstructured":"Franssen, L. E. et al. Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients. Haematologica 103, e368\u2013e371, https:\/\/doi.org\/10.3324\/haematol.2017.186601 (2018).","journal-title":"Haematologica"},{"key":"51446_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.leukres.2013.08.015","volume":"38","author":"SR Schuster","year":"2014","unstructured":"Schuster, S. R. et al. The clinical significance of cereblon expression in multiple myeloma. Leuk Res 38, 23\u201328, https:\/\/doi.org\/10.1016\/j.leukres.2013.08.015 (2014).","journal-title":"Leuk Res"},{"key":"51446_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/bjh.12622","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi, A. K. et al. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol 164, 233\u2013244, https:\/\/doi.org\/10.1111\/bjh.12622 (2014).","journal-title":"Br J Haematol"},{"key":"51446_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1097\/PAI.0000000000000246","volume":"24","author":"Y Ren","year":"2016","unstructured":"Ren, Y. et al. A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples. Appl Immunohistochem Mol Morphol 24, 695\u2013702, https:\/\/doi.org\/10.1097\/PAI.0000000000000246 (2016).","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"9","key":"51446_CR23","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.3390\/ijms18091999","volume":"18","author":"Xiubao Chang","year":"2017","unstructured":"Chang, X. et al. Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma. Int J Mol Sci 18, https:\/\/doi.org\/10.3390\/ijms18091999 (2017).","journal-title":"International Journal of Molecular Sciences"},{"key":"51446_CR24","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","volume":"128","author":"KM Kortum","year":"2016","unstructured":"Kortum, K. M. et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood 128, 1226\u20131233, https:\/\/doi.org\/10.1182\/blood-2016-02-698092 (2016).","journal-title":"Blood"},{"key":"51446_CR25","doi-asserted-by":"crossref","unstructured":"Sarah Gooding, C. C. B. et al. 2648 Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple and Gene Expression Heterogeneity. ASH Annual Meeting (2018).","DOI":"10.1182\/blood-2018-99-112644"},{"key":"51446_CR26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00005-016-0442-6","volume":"64","author":"A Butrym","year":"2016","unstructured":"Butrym, A. et al. Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma. Arch Immunol Ther Exp (Warsz) 64, 151\u2013156, https:\/\/doi.org\/10.1007\/s00005-016-0442-6 (2016).","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"51446_CR27","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/leu.2013.59","volume":"27","author":"V Sardnal","year":"2013","unstructured":"Sardnal, V. et al. A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low\/int-1 risk MDS without del(5q). Leukemia 27, 1610\u20131613, https:\/\/doi.org\/10.1038\/leu.2013.59 (2013).","journal-title":"Leukemia"},{"key":"51446_CR28","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1182\/blood-2016-06-716902","volume":"128","author":"M Han","year":"2016","unstructured":"Han, M. et al. A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma. Blood 128, 732\u2013735, https:\/\/doi.org\/10.1182\/blood-2016-06-716902 (2016).","journal-title":"Blood"},{"key":"51446_CR29","doi-asserted-by":"publisher","first-page":"24054","DOI":"10.18632\/oncotarget.25307","volume":"9","author":"A Szudy-Szczyrek","year":"2018","unstructured":"Szudy-Szczyrek, A. et al. Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients. Oncotarget 9, 24054\u201324068, https:\/\/doi.org\/10.18632\/oncotarget.25307 (2018).","journal-title":"Oncotarget"},{"key":"51446_CR30","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood.V124.21.3628.3628","volume":"124","author":"E Iskierka-Jazdzewska","year":"2014","unstructured":"Iskierka-Jazdzewska, E. et al. Cereblon (CRBN) Gene Polymorphisms Predict Clinical Response and Progression-Free Survival in Multiple Myeloma Patients Treated with Lenalidomide: A Pharmacogenetic Study of Immense Consortium. Blood 124, 3628 (2014).","journal-title":"Blood"},{"key":"51446_CR31","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1001\/jamaoncol.2018.5457","volume":"4","author":"D Kazandjian","year":"2018","unstructured":"Kazandjian, D. et al. Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial. JAMA Oncol 4, 1781\u20131783, https:\/\/doi.org\/10.1001\/jamaoncol.2018.5457 (2018).","journal-title":"JAMA Oncol"},{"key":"51446_CR32","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1182\/bloodadvances.2017005934","volume":"1","author":"S Mailankody","year":"2017","unstructured":"Mailankody, S. et al. Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Adv 1, 1911\u20131918, https:\/\/doi.org\/10.1182\/bloodadvances.2017005934 (2017).","journal-title":"Blood Adv"},{"issue":"1","key":"51446_CR33","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1182\/asheducation-2009.1.578","volume":"2009","author":"A. K. Stewart","year":"2009","unstructured":"Stewart, A. K. Novel therapies for relapsed myeloma. Hematology Am Soc Hematol Educ Program, 578\u2013586, https:\/\/doi.org\/10.1182\/asheducation-2009.1.578 (2009).","journal-title":"Hematology"},{"key":"51446_CR34","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.leukres.2015.10.007","volume":"39","author":"A Butrym","year":"2015","unstructured":"Butrym, A. et al. Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment. Leuk Res 39, 1462\u20131466, https:\/\/doi.org\/10.1016\/j.leukres.2015.10.007 (2015).","journal-title":"Leuk Res"},{"issue":"1","key":"51446_CR35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1080\/10428194.2018.1466290","volume":"60","author":"Konstantinos Dimopoulos","year":"2018","unstructured":"Dimopoulos, K. et al. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma. Leuk Lymphoma, 1\u20139, https:\/\/doi.org\/10.1080\/10428194.2018.1466290 (2018).","journal-title":"Leukemia & Lymphoma"},{"key":"51446_CR36","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/leu.2013.315","volume":"28","author":"A Thakurta","year":"2014","unstructured":"Thakurta, A. et al. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia 28, 1129\u20131131, https:\/\/doi.org\/10.1038\/leu.2013.315 (2014).","journal-title":"Leukemia"},{"issue":"2","key":"51446_CR37","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/10428194.2018.1485915","volume":"60","author":"Xiaozhong Qian","year":"2018","unstructured":"Qian, X. et al. Cereblon gene expression and correlation with clinical outcomes in patients with relapsed\/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. Leuk Lymphoma, 1\u20139, https:\/\/doi.org\/10.1080\/10428194.2018.1485915 (2018).","journal-title":"Leukemia & Lymphoma"},{"key":"51446_CR38","unstructured":"Xiaozhong Qian, M. A. D. et al. Correlative Analyses of Cereblon (CRBN), cMYC, IRF4, BLIMP1, and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM). American Society of Hematology (2017)."},{"key":"51446_CR39","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/bjh.12291","volume":"161","author":"JB Egan","year":"2013","unstructured":"Egan, J. B. et al. Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. Br J Haematol 161, 748\u2013751, https:\/\/doi.org\/10.1111\/bjh.12291 (2013).","journal-title":"Br J Haematol"},{"key":"51446_CR40","unstructured":"Sheri Skerget, B. B. et al. A Molecular Analysis of Cereblon-Related Immunomodulatory Drug Resistance in Commpass Multiple Myeloma Patients. American Society of Hematology (2017)."},{"key":"51446_CR41","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/bjh.12478","volume":"163","author":"L Lode","year":"2013","unstructured":"Lode, L. et al. Cereblon expression in multiple myeloma: not ready for prime time. Br J Haematol 163, 282\u2013284, https:\/\/doi.org\/10.1111\/bjh.12478 (2013).","journal-title":"Br J Haematol"},{"key":"51446_CR42","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188839","author":"Y Ruiz-Heredia","year":"2018","unstructured":"Ruiz-Heredia, Y. et al. Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2018.188839 (2018).","journal-title":"Haematologica"},{"key":"51446_CR43","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1021\/acs.chemrestox.6b00210","volume":"29","author":"H Yamazaki","year":"2016","unstructured":"Yamazaki, H. et al. Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-Chromosome or Hepatocytes by Two-Dimensional Electrophoresis\/Accelerator Mass Spectrometry. Chem Res Toxicol 29, 1279\u20131281, https:\/\/doi.org\/10.1021\/acs.chemrestox.6b00210 (2016).","journal-title":"Chem Res Toxicol"},{"key":"51446_CR44","doi-asserted-by":"publisher","first-page":"10625","DOI":"10.1073\/pnas.1611751113","volume":"113","author":"D Millrine","year":"2016","unstructured":"Millrine, D., Tei, M., Gemechu, Y. & Kishimoto, T. Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN production. Proc Natl Acad Sci USA 113, 10625\u201310630, https:\/\/doi.org\/10.1073\/pnas.1611751113 (2016).","journal-title":"Proc Natl Acad Sci USA"},{"key":"51446_CR45","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s41589-018-0129-x","volume":"14","author":"ME Matyskiela","year":"2018","unstructured":"Matyskiela, M. E. et al. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nat Chem Biol 14, 981\u2013987, https:\/\/doi.org\/10.1038\/s41589-018-0129-x (2018).","journal-title":"Nat Chem Biol"},{"key":"51446_CR46","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00280-017-3323-8","volume":"80","author":"TM Sissung","year":"2017","unstructured":"Sissung, T. M. et al. Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. Cancer Chemother Pharmacol 80, 217\u2013221, https:\/\/doi.org\/10.1007\/s00280-017-3323-8 (2017).","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"51446_CR47","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","volume":"1","author":"Neha Korde","year":"2015","unstructured":"Korde, N. et al. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncol, https:\/\/doi.org\/10.1001\/jamaoncol.2015.2010 (2015).","journal-title":"JAMA Oncology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51446-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51446-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51446-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T14:46:31Z","timestamp":1671288391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51446-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["51446"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-51446-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"assertion":[{"value":"10 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.L. receives grant support from NIH, FDA, MMRF, IMF, LLS, Perelman Family Foundation, Rising Tides Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, and Karyopharm. He is a member of the following Honoraria\/Advisory Boards: Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, and Pfizer. He also serves as Chairman for \u201cMedscape Myeloma\u201d (2014-ongoing) and is a member of the Independent Data Monitoring Committee (IDMC) for Takeda, Merck, Janssen, and Theradex. All other authors declare no potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14884"}}